The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gareeva A.E.

Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences;
Kemerovo State University;
Russian Medical Academy of Continuing Professional Education;
Bashkir State Medical University

Nasibullin T.R.

Kemerovo State University

Pozdnyakov S.A.

Moscow Research and Practical Center of Addiction Medicine

Borodina L.S.

Republican Narcological Dispensary No. 1

Mikhailova E.G.

Republican Narcological Dispensary No. 1

Gindullina P.A.

Bashkir State Medical University

Timerbulatov I.F.

Russian Medical Academy of Continuing Professional Education;
Central Clinical Psychiatric Hospital named after F.A. Usoltsev;
Russian University of Medicine

Effect of polymorphic variants of the HTR2A gene on the effectiveness and safety of sertraline in patients with mixed anxiety-depressive disorder

Authors:

Gareeva A.E., Nasibullin T.R., Pozdnyakov S.A., Borodina L.S., Mikhailova E.G., Gindullina P.A., Timerbulatov I.F.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8): 75‑84

DOI: 10.17116/jnevro202512508175

Read: 577 times

Buy for 300₽
Contact the author
Table of contents

EFFECT OF POLYMORPHIC VARIANTS OF THE HTR2A GENE ON THE EFFECTIVENESS AND SAFETY OF SERTRALINE IN PATIENTS WITH MIXED ANXIETY-DEPRESSIVE DISORDER
EFFECT OF POLYMORPHIC VARIANTS OF THE HTR2A GENE ON THE EFFECTIVENESS AND SAFETY OF SERTRALINE IN PATIENTS WITH MIXED ANXIETY-DEPRESSIVE DISORDER

To cite this article:

Gareeva AE, Nasibullin TR, Pozdnyakov SA, Borodina LS, Mikhailova EG, Gindullina PA, Timerbulatov IF. Effect of polymorphic variants of the HTR2A gene on the effectiveness and safety of sertraline in patients with mixed anxiety-depressive disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8):75‑84. (In Russ.)
https://doi.org/10.17116/jnevro202512508175

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Anti­depressants as addi­tional drugs for human brain gliomas. Burdenko's Journal of Neurosurgery. 2024;(6):97-102
Pharmacogenetic testing for personalized statin prescription in Moscow. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):49-55
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
Abstract:

OBJECTIVE

To identify pharmacogenetic markers of the effectiveness and safety of sertraline pharmacotherapy at polymorphic loci (−1438G>A, rs6311), (102c>T, rs6313), (1354C/T, rs6314), (rs7997012 G>A) of the HTR2A gene in patients with mixed anxiety-depressive disorder from the Republic of Bashkortostan.

MATERIAL AND METHODS

The study included 100 patients treated with sertraline. The effectiveness and safety of sertraline therapy in patients were assessed using standardized psychometric scales on the day before the start of therapy and then for 42 days. Four polymorphic loci, rs6311, rs6313, rs6314, and rs7997012, of the HTR2A gene were tested using real-time polymerase chain reaction (PCR).

RESULTS

Significant differences in the severity of depressive symptoms were found between carriers of different rs6311 genotypes of the HTR2A gene at the beginning of the study (p<0.05) and on day 42 of the study (p<0.001). More severe depressive symptoms were observed in carriers of the rs6311*A/A (p<0.05) and rs6313*T/T (p<0.001) genotypes. Statistically significant differences were observed between carriers of different rs6311 and rs6313 genotypes of the HTR2A gene in the severity of anxiety symptoms on all study days. More severe anxiety symptoms were observed in carriers of the rs6311*A/A (p<0.001) and rs6313*T/T (p<0.001) genotypes. The rs6311*A/A and rs6313*T/T genotypes can be considered markers of low effectiveness for anxiety and depressive symptoms and markers of risk of adverse reactions (ADRs) when taking sertraline. The rs6314*C/T and rs7997012*G/G genotypes can be considered markers of the ADR risk during sertraline therapy.

CONCLUSION

The study showed that the studied polymorphic variants of the HTR2A gene can be predictors of the effectiveness and safety of sertraline in the treatment of mixed anxiety-depressive disorder.

Keywords:

antidepressants
pharmacogenetics
selective serotonin reuptake inhibitors
sertraline

Authors:

Gareeva A.E.

Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences;
Kemerovo State University;
Russian Medical Academy of Continuing Professional Education;
Bashkir State Medical University

Nasibullin T.R.

Kemerovo State University

Pozdnyakov S.A.

Moscow Research and Practical Center of Addiction Medicine

Borodina L.S.

Republican Narcological Dispensary No. 1

Mikhailova E.G.

Republican Narcological Dispensary No. 1

Gindullina P.A.

Bashkir State Medical University

Timerbulatov I.F.

Russian Medical Academy of Continuing Professional Education;
Central Clinical Psychiatric Hospital named after F.A. Usoltsev;
Russian University of Medicine

Received:

24.03.2025

Accepted:

02.05.2025

Close metadata

References:

  1. Kasper S, Eckert A. Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data. Eur Arch Psychiatry Clin Neurosci. Published online October 25, 2024. https://doi.org/10.1007/s00406-024-01923-8
  2. Poweleit EA, Aldrich SL, Martin LJ, et al. Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. J Child Adolesc Psychopharmacol. 2019;29(5):348-361.  https://doi.org/10.1089/cap.2019.0017
  3. Singh AB, Bousman CA. Antidepressant Pharmacogenetics. Am J Psychiatry. 2017;174(5):417-418.  https://doi.org/10.1176/appi.ajp.2017.17020173
  4. Wan YS, Zhai XJ, Tan HA, et al. Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis. Pharmacogenomics J. 2021;21(2):200-215.  https://doi.org/10.1038/s41397-020-00197-2
  5. Uher R, Huezo-Diaz P, Perroud N, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;(4):225-233.  https://doi.org/10.1038/tpj.2009.12
  6. Sun Y, Tao S, Tian S, et al. Serotonin 2A receptor polymorphism rs3803189 mediated by dynamics of default mode network: a potential biomarker for antidepressant early response. J Affect Disord. 2021;283:130-138.  https://doi.org/10.1016/j.jad.2021.01.047
  7. Gassó P, Blázquez A, Rodríguez N, et al. Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism. J Child Adolesc Psychopharmacol. 2018;28(10):711-718.  https://doi.org/10.1089/cap.2018.0004
  8. Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68.  https://doi.org/10.1002/cpt.2903
  9. Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018;29(11):113-119.  https://doi.org/10.2147/PGPM.S160763
  10. Gareeva AE, Borodina LS, Pozdnyakov SA, et al. Pharmacogenomic and Pharmacometabolomic Biomarkers of the Efficacy and Safety of Antidepressants: Focus on Selective Serotonin Reuptake Inhibitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):26-35. (In Russ.). https://doi.org/10.17116/jnevro202412406126
  11. Lin JY, Jiang MY, Kan ZM, et al. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430-438.  https://doi.org/10.1016/j.jad.2014.06.012
  12. Niitsu T, Fabbri C, Bentini F, et al. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:183-194.  https://doi.org/10.1016/j.pnpbp.2013.05.011
  13. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53(4):186-195.  https://doi.org/10.1159/000094727
  14. Sato T, Hirano S, Narita T, et al. Temperament and character inventory dimensions as a predictor of response to antidepressant treatment in major depression. J Affect Disord. 1999;56(2-3):153-161.  https://doi.org/10.1016/s0165-0327(99)00047-6
  15. Badamasi IM, Lye MS, Ibrahim N, et al. Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder. Pharmacogenomics J. 2021;21(4):498-509.  https://doi.org/10.1038/s41397-021-00228-6
  16. Brunoni AR, Carracedo A, Amigo OM, et al. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Braz J Psychiatry. 2020;42(2):128-135.  https://doi.org/10.1590/1516-4446-2019-0620
  17. Basu A, Chadda RK, Sood M, et al. Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study. Indian J Med Res. 2015;142(1):40-45.  https://doi.org/10.4103/0971-5916.162094
  18. Zou Z, Huang Y, Wang J, et al. The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder. BMC Psychiatry. 2020;20(1):388.  https://doi.org/10.1186/s12888-020-02790-y
  19. Yuan R, Yuan F, Ren D, et al. HTR1A and HTR2A variants may not predict venlafaxine treatment response in China Han population with major depressive disorder. Psychiatry Res. 2018;270:1179-1180. https://doi.org/10.1016/j.psychres.2018.10.038
  20. Minov C, Baghai TC, Schüle C, et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett. 2001;303(2):119-122.  https://doi.org/10.1016/s0304-3940(01)01704-9
  21. Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004;9(9):879-889.  https://doi.org/10.1038/sj.mp.4001502
  22. Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009;9(1):61-70.  https://doi.org/10.1038/sj.tpj.6500491
  23. Qesseveur G, Petit AC, Nguyen HT, et al. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. Neuropharmacology. 2016;105:142-153.  https://doi.org/10.1016/j.neuropharm.2015.12.022
  24. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-814.  https://doi.org/10.1086/503820
  25. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35(3):727-740.  https://doi.org/10.1038/npp.2009.180
  26. Lucae S, Ising M, Horstmann S, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol. 2010;20(1):65-68.  https://doi.org/10.1016/j.euroneuro.2009.08.006
  27. Lohoff FW, Aquino TD, Narasimhan S, et al. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13(1):21-26.  https://doi.org/10.1038/tpj.2011.47
  28. Noro M, Antonijevic I, Forray C, et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol. 2010;25(4):228-231.  https://doi.org/10.1097/YIC.0b013e328338bcf4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.